NasdaqGM - Nasdaq Real Time Price • USD
89bio, Inc. (ETNB)
At close: April 25 at 4:00 PM EDT
After hours: April 25 at 5:39 PM EDT
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Rohan Palekar | CEO & Director | 1.06M | -- | 1966 |
| Mr. Quoc Le-Nguyen | Chief Technical Operations Officer & Head of Quality | 702.87k | -- | 1968 |
| Dr. Harry Mansbach M.D. | Chief Medical Officer | 732.87k | -- | 1965 |
| Mr. Ryan Stephen Martins | Chief Financial Officer | -- | -- | 1979 |
| Mr. Shiva K. Natarajan CPA | Senior Vice President of Finance & Principal Accounting Officer | -- | -- | 1966 |
| Ms. Annie J. Chang M.B.A. | VP of Investor Relations & Corporate Communications | -- | -- | -- |
| Ms. Amanda Kurihara | Vice President of People & Culture | -- | -- | -- |
| Ms. Yun Bai Ph.D. | VP and Head of Chemistry, Manufacturing & Controls ( CMC ) | -- | -- | -- |
| Ms. Melissa Abel | Senior Vice President of Commercial Strategy | -- | -- | -- |
| Mr. Paul Shin | Senior Vice President of R&D Operations | -- | -- | -- |
89bio, Inc.
142 Sansome Street
Second Floor
San Francisco, CA 94104
United States
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 70
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.
Corporate Governance
89bio, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 8. The pillar scores are Audit: 6; Board: 7; Shareholder Rights: 9; Compensation: 8.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Recent Events
- Apr 19, 2024ARS: Annual Report to ShareholdersSee Full Filing
- Apr 17, 2024DEF 14A: Proxy StatementsSee Full Filing
- Apr 10, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Mar 08, 2024S-8: Offering RegistrationsSee Full Filing
- Mar 01, 2024NT 10-K: Periodic Financial ReportsSee Full Filing
Upcoming Events
May 02, 2024 - May 06, 2024
89bio, Inc. Earnings Call
Related Tickers
AKRO Akero Therapeutics, Inc.
18.93
-6.56%
DAWN Day One Biopharmaceuticals, Inc.
13.21
-13.03%
TERN Terns Pharmaceuticals, Inc.
4.6400
-2.32%
MLTX MoonLake Immunotherapeutics
42.25
-0.42%
CYTK Cytokinetics, Incorporated
64.80
-3.02%
FOLD Amicus Therapeutics, Inc.
10.17
-3.51%
MDGL Madrigal Pharmaceuticals, Inc.
194.38
-5.02%
QURE uniQure N.V.
4.5400
-0.44%
EWTX Edgewise Therapeutics, Inc.
15.94
-1.06%
LBPH Longboard Pharmaceuticals, Inc.
19.25
-2.53%